Sanofi, GSK Seek Vaccine Authorization as Both Primary Series and Booster

Sanofi and GlaxoSmithKline (GSK) will very soon be taking their COVID-19 vaccine candidate to U.S. and European regulators as both a primary series and booster, touting its 58 percent efficacy against symptomatic disease as proof that the shot works in a world with multiple COVID-19 variants.
Source: Drug Industry Daily